The leading assignee in this dataset holds 156 of the 7,397 records in scope, with the fifth-ranked assignee at 123 and the tenth at 85. Together the top 5 hold 9.7% of all records and the top 10 hold 16.5%, which means no single company dominates the field the way a leader might in a narrower niche. The remaining records are spread across a long tail of smaller filers, including academic and CDMO-affiliated entities not in the ranked leaders.

Filings peaked at 498 records in 2019 and have declined since, with the most recent complete comparison showing a -46% drop from 451 records in 2021 to 243 in 2024. The 2025 and 2026 figures in the raw trend look lower still, but that is expected: publication typically lags filing by around 18 months, so those final years will revise upward as more applications publish. The 2021-to-2024 window is the most reliable recent signal, and it does point to a genuine cooling.

Formulation claims, largely filed under A61K, cover the biologic's stabilizers, excipients and buffer chemistry and touch 88.5% of the 7,397 records in this landscape. Drying-process and equipment claims, filed under F26B, cover the freeze-dryer cycle itself — shelf temperature ramps, primary and secondary drying parameters, chamber pressure control — and appear on only 14.5% of records. That gap suggests process-engineering routes to cake-quality improvements carry comparatively less prior art than formulation routes.

NZ803099A, assigned to Advaxis, Inc. and published 2023-09-29, claims methods and compositions for lyophilizing bacteria or Listeria strains, including Listeria monocytogenes, along with formulations for that lyophilization and methods of preparing the frozen bacteria beforehand. It is a live-bacterial-strain lyophilization claim rather than a general antibody or protein formulation claim, so its blocking effect is narrow to that class of biologic. Anyone developing freeze-dried live bacterial therapeutics, rather than freeze-dried proteins or antibodies, is the audience most likely to need to check around it.

Relative to the dense formulation-claim crowd under A61K, sub-areas like non-invasive residual moisture sensing, reconstitution-time claims tied to specific excipient ratios, and container-closure interactions during freeze-drying show thinner coverage. F26B drying-process claims overall sit at just 14.5% of the 7,397 records, well below formulation's 88.5%, which is the clearest quantitative signal that process-side claim space remains comparatively open. Confirming true freedom-to-operate in any specific sub-area still requires a targeted search beyond this landscape's scope.